Skip to main content

Table 1 Patients’ characteristics

From: Intermittent and episode-driven use of pranlukast to reduce the frequency of wheezing in atopic children: a randomized, double-blind, placebo-controlled trial

 

Total (n = 77)

Pranlukast (n = 37)

Placebo (n = 40)

P value

Age (y), mean (SD)

1.9 ± 0.6

1.8 ± 0.5

1.9 ± 0.6

0.71*1

Males, no. (%)

56 (73)

29 (78)

27 (68)

0.28*2

Comorbidity*3

    

Food allergy, no. (%)

39 (51)

20 (54)

19 (48)

0.57*2

Atopic dermatitis, no. (%)

32 (42)

14 (38)

18 (45)

0.52*1

Total IgE (IU), median (25% – 75%)

214 (76 – 585)

224 (64 – 536)

204 (106 – 771)

0.77*4

Allergen-specific IgE (IU), median (25% – 75%)

    

Mite

5.8 (0.4 – 49)

5.6 (0.4 – 48)

6.1 (0.3 – 49)

0.42*4

Egg

5.6 (1.1 – 26)

12 (0.9 – 29)

3.2 (1.3 – 15)

0.26*4

Milk

0.7 (0. 4 – 4.3)

1.3 (0.4 – 9.9)

0.7 (0.4 – 2.5)

0.34*4

Wheat

0.6 (0.3 – 3.1)

0.5 (0.3 – 3.5)

0.7 (0.3 – 2.2)

0.96*4

Eosinophils (%), median (25% – 75%)

3.6 (1.4 – 5.0)

4.0 (1.4 – 5.0)

3.3 (1.0 – 5.0)

0.71*4

  1. *1P value was calculated by Student’s t-test. *2P value was calculated by the χ2 test. *3Comorbidity was diagnosed by collaborating pediatricians. *4P value was calculated by the Mann–Whitney test.